We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
Cayman Ar231453, 50mg
Product Description
Lysine-specific demethylase 1 (LSD1) is a protein lysine demethylase that specifically demethylates histone H3 lysine 4 (H3K4), resulting in transcriptional repression. SP-2509 is a reversible inhibitor of LSD1 (IC50 = 13 nM). It has no effect on monoamine oxidases A and B. SP-2509 attenuates the binding of LSD1 to CoREST, allowing increased methylation of H3K4 and driving increased expression of p21, p27, and CCAAT/enhancer binding protein α in cultured acute myeloid leukemia (AML) cells., It improves survival of mice with AML xenografts when given (25 mg/kg biweekly via intraperitoneal injection) for three weeks. Co-treatment of SP2509 with the pan-HDAC inhibitor panobinostat (Item No. ) synergistically kills AML cells in vitro and improves survival of mice engrafted with AML cells.,
WARNING This product is not for human or veterinary use.
Technical Information
- HCI-2509
- LSD1 Inhibitor VII
- DMF: 50 mg/ml
- DMSO: 25 mg/ml
Shipping & Storage Information
| SKU | CAYM-34898-50 |
|---|---|
| Featured | No |
| Supplier Part Number | 34898-50 |
| UM | EA |
| UNSPSC | 12352200 |
| Manufacturer | Cayman |
| MSDS URL | Click here |
| Temperature | -20 |
| Refrigerated-Frozen | Refrigerated |
| CountryOfOrigin | United States |
| ProductLine | CAYM |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 2 |
| Hazardous | N |
| CAS Number | 733750-99-7 |
| Energy Star | No |
| Green | No |
| ACT Ecolabel | No |
| Controlled | N |